Drug intelligence / Profile preview

nu6027

Development stage: Preclinical
Modality: Small Molecules

Overview

NU6027 is a small molecule inhibitor primarily known for its activity against cyclin-dependent kinase 2 (CDK2) and ataxia telangiectasia and Rad3-related protein (ATR). It has been studied as a potential anticancer agent due to its ability to sensitize tumor cells to DNA damage by inhibiting ATR-mediated DNA damage response pathways. This compound is used mainly in research settings to probe cell cycle regulation and DNA repair mechanisms[1][5][9].

Other names: 6-cyclohexylmethyloxy-5-nitroso-pyrimidine-2,4-diamine6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine2,6-diamino-4-cyclohexylmethoxy-5-nitrosopyrimidine4-cyclohexylmethoxy-2,6-diamino-5-nitrosopyrimidine

Targets

CDK2 (Cyclin-dependent kinase 2)CDK1 (Cyclin-dependent kinase 1)DNA-PK (DNA-dependent protein kinase)

Beyond the preview

Go deeper on nu6027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nu6027.

Explore the full profile